The latest announcement is out from GlaxoSmithKline ( (GB:GSK) ).
GSK plc has announced the repurchase of 542,550 of its ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This transaction, completed on February 28, 2025, is part of a non-discretionary agreement and contributes to the company’s strategy of managing its capital structure. The shares will be held in treasury, impacting the total number of voting rights and potentially affecting shareholder interests in line with the Financial Conduct Authority’s rules.
More about GlaxoSmithKline
GlaxoSmithKline (GSK) is a global healthcare company engaged in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. The company focuses on innovative solutions in the healthcare sector, aiming to improve the quality of human life by enabling people to do more, feel better, and live longer.
YTD Price Performance: 10.14%
Average Trading Volume: 7,985,177
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: £59.81B
Find detailed analytics on GSK stock on TipRanks’ Stock Analysis page.